Ann Childress
Center for Psychiatry And Behavioral Medicine Inc. · Vector Clinical Trials · Principal Investigator
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
16
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
14 more share only the name and are not shown
Trial papers
92
PubMed author-name match
Trials
Studies that name Ann Childress as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:27 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07169162 · ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity DisorderAytu BioPharma, Inc. · withdrawn · Attention Deficit Hyperactivity Disorder · principal investigator
- Ph4NCT07044609 · A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODDLas Vegas Medical Research, LLC DBA Vector Clinical Trials · not yet recruiting · Attention-deficit/Hyperactivity Disorder, Oppositional Defiant Disorder in Children · principal investigator
- Ph4NCT05721235 · A Safety/Tolerability and PK Study With Azstarys® in Children With ADHDCorium, Inc. · completed · Attention Deficit/Hyperactivity Disorder · principal investigator
- Ph4NCT05685732 · An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHDCorium, Inc. · completed · Attention Deficit/Hyperactivity Disorder · principal investigator
- Ph3NCT05631626 · Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.Cingulate Therapeutics · completed · ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined · principal investigator
- N/ANCT05296473 · Guided ADHD Therapy for Managing the Extent and Severity of SymptomsLumos Labs, Inc. · completed · ADHD · principal investigator
- Ph3NCT05286762 · Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301Cingulate Therapeutics · completed · ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type · study chair
- Ph3NCT03460652 · KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHDZevra Therapeutics · completed · ADHD · principal investigator
- Ph2NCT02884544 · A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHDIronshore Pharmaceuticals and Development, Inc · completed · Attention-Deficit Hyperactivity Disorder (ADHD) · principal investigator
- Ph4NCT02683265 · A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHDRhodes Pharmaceuticals, L.P. · completed · Attention Deficit Disorder With Hyperactivity · principal investigator
- Ph4NCT02677519 · A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHDRhodes Pharmaceuticals, L.P. · unknown · Attention Deficit Disorder With Hyperactivity · principal investigator
- Ph3NCT02493777 · A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom SettingIronshore Pharmaceuticals and Development, Inc · completed · Attention Deficit Hyperactivity Disorder · principal investigator
- Ph3NCT02255513 · A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHDIronshore Pharmaceuticals and Development, Inc · completed · Attention Deficit Hyperactivity Disorder · principal investigator
- Ph1/Ph2NCT01907360 · Pharmacokinetics of HLD200 in Children and Adolescents With ADHDIronshore Pharmaceuticals and Development, Inc · completed · Attention-Deficit Hyperactivity Disorder · principal investigator
- Ph2NCT00557011 · NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHDNew River Pharmaceuticals · completed · Attention Deficit Disorder With Hyperactivity · principal investigator
- Ph3NCT00141063 · Safety and Efficacy Study of Dexmethylphenidate in Children With ADHDNovartis · completed · ADHD · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 14 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:27 UTC. The ranking covers the 200 most relevant of 92 PubMed records, and a shared surname and initials can bring in a namesake. All 92 on PubMed
- Brain metabolic changes during cigarette craving.Arch Gen Psychiatry · 2002357 citationsRCR 9.9
- 309 citationsRCR 9.5
- Integrating systemic cue exposure with standard treatment in recovering drug dependent patients.Addict Behav · 1990237 citationsRCR 8.4
- Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.Biol Psychiatry · 2007155 citationsRCR 5.5
- Effects of varenicline on smoking cue–triggered neural and craving responses.Arch Gen Psychiatry · 2011134 citationsRCR 4.7
- Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry · 2011100 citationsRCR 4.3
- The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.Drug Alcohol Depend · 200983 citationsRCR 2.7
- A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry · 201282 citationsRCR 3.4
- Pharmacological and behavioral treatments of cocaine dependence: controlled studies.J Clin Psychiatry · 198882 citationsRCR 4.5
- Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.CNS Spectr · 200867 citationsRCR 2.4